AR019669A1 - Uso de diazepinas para la preparacion de medicamentos para el tratamiento de estados patologicos o enfermedades en los cuales esta involucrado por lo menosuno de los receptores de somatostatina, diazepinas utilizadas en dicha preparacion y medicamento y composicion farmaceutica que los contienen. - Google Patents

Uso de diazepinas para la preparacion de medicamentos para el tratamiento de estados patologicos o enfermedades en los cuales esta involucrado por lo menosuno de los receptores de somatostatina, diazepinas utilizadas en dicha preparacion y medicamento y composicion farmaceutica que los contienen.

Info

Publication number
AR019669A1
AR019669A1 ARP990102861A ARP990102861A AR019669A1 AR 019669 A1 AR019669 A1 AR 019669A1 AR P990102861 A ARP990102861 A AR P990102861A AR P990102861 A ARP990102861 A AR P990102861A AR 019669 A1 AR019669 A1 AR 019669A1
Authority
AR
Argentina
Prior art keywords
radical
aryl
hydrogen atom
preparation
alkyl
Prior art date
Application number
ARP990102861A
Other languages
English (en)
Original Assignee
Sod Conseils Rech Applic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic
Publication of AR019669A1 publication Critical patent/AR019669A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/22Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Uso para la preparacion de medicamentos para el tratamiento de estados patologicos o enfermedades en los cuales está involucrado por lo menos uno de losreceptores de somatostatina, de diazepinas de formula general (1) en el cual W representa el átomode hidrogeno o un radical de formula R-X-C(Y), R representaun radical arilo o heteroarilo, estando los radicales arilo y heteroarilo sustituidos optativamente; X representa un radical de formula -(CH2)n-Z en el cual Zrepresenta un enlace covalente,NH, O o S y n es un entero de 0 y 2; Y representa O o S, R1 representa uno o más grupos idénticos o diferentes, elegidos entre:un átomo de hidrogeno, hidroxi, un radical halo, un radical alquilo inferior y alcoxi inferior; R2a y R2b representan, independientemente, un átomo dehidrogeno; un radical alquilo inferior, alquenilo inferior o alquinilo inferior, estando los radicales alquilo, alquenilo y alquinilo optativamente sustituidoso un radical R21Z21- en el cual Z21 representa O, C(O), OC(O), S, R21 representa un átomo de hidrogeno, un radical alquilo, arilo o arilalquilo inferior; R3representa un átomo de hidrogeno, un radical halo, nitro o ciano, un radical alquilo con 1 a 10 átomos de carbono, radicales alquenilo inferior, alquiniloinferior, cicloalquilo, cicloalquilalquilo, arilo, arilalquilo, ariloxialquilo inferior, heteroarilo o heteroarilalquilo, estando los radicales alquilo,alquenilo, alquilo, cicloalquilo, arilo y heteroarilo optativamente sustituidos; o un radical R31Z31-en el cual Z31 representa O, C(O), OC(O), S, y R31representa un átomo de hidrogeno, un radical alquilo inferior, arilo o arilalquilo inferior , o una sal de este producto, para la preparacion de un medicamentopara tratar estados patologicos o enfermedades en las cuales están involucrados uno (o más) receptores de somatostatina. Dado que los desordenes patologicosasociados con la somatostatina son numerosos, resulto importante hallar compuesto que tengan afinidad con receptores de somatostatina.Como nuevos compuestoscomprendidos por la formula (1), se encuentran los de la formula general (2) en la cual W representa el átomo de hidrogeno o un radical de formula
ARP990102861A 1998-06-15 1999-06-15 Uso de diazepinas para la preparacion de medicamentos para el tratamiento de estados patologicos o enfermedades en los cuales esta involucrado por lo menosuno de los receptores de somatostatina, diazepinas utilizadas en dicha preparacion y medicamento y composicion farmaceutica que los contienen. AR019669A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9807509A FR2779652B1 (fr) 1998-06-15 1998-06-15 Utilisation de diazepines pour la preparation de medicaments destines a traiter les etats pathologiques ou les maladies dans lesquels un des recepteurs de la somatostatine est implique

Publications (1)

Publication Number Publication Date
AR019669A1 true AR019669A1 (es) 2002-03-13

Family

ID=9527389

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990102861A AR019669A1 (es) 1998-06-15 1999-06-15 Uso de diazepinas para la preparacion de medicamentos para el tratamiento de estados patologicos o enfermedades en los cuales esta involucrado por lo menosuno de los receptores de somatostatina, diazepinas utilizadas en dicha preparacion y medicamento y composicion farmaceutica que los contienen.

Country Status (19)

Country Link
US (1) US7015213B1 (es)
EP (1) EP1087978A1 (es)
JP (1) JP2002518400A (es)
KR (1) KR20010052836A (es)
CN (1) CN100348600C (es)
AR (1) AR019669A1 (es)
AU (1) AU758206B2 (es)
CA (1) CA2335724A1 (es)
FR (1) FR2779652B1 (es)
HK (1) HK1039780A1 (es)
HU (1) HUP0102300A3 (es)
IL (1) IL139954A0 (es)
MY (1) MY118652A (es)
NO (1) NO20006352D0 (es)
NZ (1) NZ509313A (es)
PL (1) PL344831A1 (es)
RU (1) RU2229299C2 (es)
TW (1) TW513434B (es)
WO (1) WO1999065917A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6987105B2 (en) * 2000-04-28 2006-01-17 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthesis and use of thienotriazolodiazepines
WO2002057241A1 (en) * 2000-12-22 2002-07-25 Bayer Pharmaceuticals Corporation 8-(AMINOALKOXYMINO)-8H-DIBENZO[a,e]TRIAZOLO[4,5-c]CYCLOHEPTENES AS GROWTH HORMONE SECRETAGOGUES
WO2009084693A1 (ja) 2007-12-28 2009-07-09 Mitsubishi Tanabe Pharma Corporation 抗癌剤
BR112012029057A2 (pt) 2010-05-14 2020-10-13 Dana-Farber Cancer Institute, Inc. composições e métodos de tratamento de leucemia
CA2799381A1 (en) 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Male contraceptive compositions and methods of use
EP2902030B1 (en) 2010-05-14 2016-09-14 Dana-Farber Cancer Institute, Inc. Thienotriazolodiazepine compounds for treating neoplasia
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
US9249161B2 (en) 2010-12-02 2016-02-02 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
US9422292B2 (en) 2011-05-04 2016-08-23 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
WO2012174487A2 (en) 2011-06-17 2012-12-20 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
TWI602820B (zh) 2012-06-06 2017-10-21 星宿藥物公司 溴域抑制劑及其用途
EP2864336B1 (en) 2012-06-06 2016-11-23 Constellation Pharmaceuticals, Inc. Benzo[b]isoxazoloazepine bromodomain inhibitors and uses thereof
BR112016001457A2 (pt) 2013-07-25 2017-08-29 Dana Farber Cancer Inst Inc Inibidores de fatores de transcrição e usos dos mesmos
US11446309B2 (en) 2013-11-08 2022-09-20 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors
RU2016134947A (ru) 2014-01-31 2018-03-01 Дана-Фарбер Кансер Институт, Инк. Производные диаминопиримидин бензолсульфона и их применение
JP2017504651A (ja) 2014-01-31 2017-02-09 ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド ジアゼパン誘導体の使用
WO2015131113A1 (en) * 2014-02-28 2015-09-03 Tensha Therapeutics, Inc. Treatment of conditions associated with hyperinsulinaemia
EP3157928B1 (en) 2014-06-20 2019-02-13 Constellation Pharmaceuticals, Inc. Crystalline forms of 2-((4s)-6-(4-chlorophenyl)-1-methyl-4h-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide
JP2017525759A (ja) 2014-08-08 2017-09-07 ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド ジヒドロプテリジノン誘導体およびその使用
JP2017526741A (ja) 2014-08-08 2017-09-14 ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド ジアゼパン誘導体およびその使用
WO2016069578A1 (en) 2014-10-27 2016-05-06 Tensha Therapeutics, Inc. Bromodomain inhibitors
WO2016201370A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
BR112018004617A2 (pt) 2015-09-11 2018-09-25 Dana Farber Cancer Inst Inc acetamida tienotriazoldiazepinas e usos das mesmas
RU2750164C2 (ru) * 2015-09-11 2021-06-22 Дана-Фарбер Кэнсер Инститьют, Инк. Цианотиенотриазолодиазепины и пути их применения
CR20180336A (es) 2015-11-25 2018-08-06 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos
JOP20200030A1 (ar) * 2017-09-07 2020-02-12 Eisai R&D Man Co Ltd مركب خماسي الحلقة
AU2020233452A1 (en) 2019-03-05 2021-09-02 Eisai R&D Management Co., Ltd. Salt of pentacyclic compound and crystals thereof
EA202191966A1 (ru) 2019-03-05 2021-12-08 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Пентациклическое гетероциклическое соединение
CN111533745A (zh) * 2020-05-20 2020-08-14 成都药明康德新药开发有限公司 叔丁基-3-(氨基甲基)二氢-5h-三唑并二氮杂卓-8(9h)-甲酸基酯制法
AU2021379248A1 (en) 2020-11-16 2023-06-22 Boehringer Ingelheim International Gmbh Cyclopentathiophene carboxamide derivatives as platelet activating factor receptor antagonists
US11992494B2 (en) 2021-12-22 2024-05-28 Boehringer Ingelheim International Gmbh Cyclopentathiophene carboxamide derivatives as platelet activating factor receptor antagonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI95708C (fi) * 1988-10-31 1996-03-11 Eisai Co Ltd Analogiamenetelmä 1,4-diatsepiinijohdannaisen ja sen farmaseuttisesti sopivan suolan valmistamiseksi
GB8907256D0 (en) * 1989-03-31 1989-05-17 Rech Et D Applic Scient Scras New derivatives of hetrazepine as anti-asthmatic anti-allergic and gastro-intestinal protectors
OA09202A (fr) * 1990-04-02 1992-06-30 Sod Conseils Rech Applic Procédé de préparation des nouveaux dérivés de la thiéno-triazolo-diazépine.
DE4107521A1 (de) * 1991-03-08 1992-09-10 Boehringer Ingelheim Kg Neue acylaminosubstituierte hetrazepine
EP0638560A4 (en) * 1991-10-11 1995-03-29 Yoshitomi Pharmaceutical MEDICINE FOR OSTEOPOROSIS AND DIAZEPINE COMPOUND *.
AU4772497A (en) * 1996-10-31 1998-05-22 Novo Nordisk A/S Constrained somatostatin agonists and antagonists

Also Published As

Publication number Publication date
CN1309657A (zh) 2001-08-22
CA2335724A1 (fr) 1999-12-23
MY118652A (en) 2004-12-31
EP1087978A1 (fr) 2001-04-04
US7015213B1 (en) 2006-03-21
IL139954A0 (en) 2002-02-10
HUP0102300A3 (en) 2002-10-28
NZ509313A (en) 2002-11-26
HUP0102300A2 (hu) 2001-11-28
NO20006352L (no) 2000-12-13
FR2779652A1 (fr) 1999-12-17
AU758206B2 (en) 2003-03-20
RU2229299C2 (ru) 2004-05-27
CN100348600C (zh) 2007-11-14
KR20010052836A (ko) 2001-06-25
TW513434B (en) 2002-12-11
JP2002518400A (ja) 2002-06-25
HK1039780A1 (zh) 2002-05-10
AU4149599A (en) 2000-01-05
NO20006352D0 (no) 2000-12-13
FR2779652B1 (fr) 2001-06-08
PL344831A1 (en) 2001-11-19
WO1999065917A1 (fr) 1999-12-23

Similar Documents

Publication Publication Date Title
AR019669A1 (es) Uso de diazepinas para la preparacion de medicamentos para el tratamiento de estados patologicos o enfermedades en los cuales esta involucrado por lo menosuno de los receptores de somatostatina, diazepinas utilizadas en dicha preparacion y medicamento y composicion farmaceutica que los contienen.
UY28144A1 (es) Agentes terapéuticos
UY28150A1 (es) Agentes terapeuticos
ECSP034642A (es) Derivados de tetralona como agentes antitumorales
AR007828A1 (es) Compuestos derivados de piridilpirrol, procedimiento de preparacion y composiciones farmaceuticas conteniendo los mismos
AR036032A1 (es) Compuesto derivado de quinolina, composicion que lo comprende; uso del mismo en la fabricacion de medicamentos, proceso para prepararlo, y metodo para detectar y seleccionar un agente que module la actividad del mif
HK1084024A1 (en) Bis (thio-hydrazide amide) compounds for treating multi-drug resistant cancer
MXPA04009784A (es) Tiazolidin-4-carbonitrilos y analogos y su uso como inhibidores de dipeptidil-peptidas.
CY1106674T1 (el) Αζαδικυκλικοι ετεροκυκλοι σαν ρυθμιστες υποδοχεα κανναβινοειδους
BRPI0409198A (pt) derivados quinolin-2-ona para o tratamento de doenças de vias aéreas
EA200500174A1 (ru) Новые производные бензимидазола, полезные в качестве антипролиферативных агентов
AR054475A1 (es) Fenilfosfatos sustituidos como profarmacos mutuos de esteroides y (beta)-agonistas para el tratamiento de la inflamacion pulmonar y la broncoconstriccion
UY28369A1 (es) Agentes terapéuticos
ECSP066405A (es) Compuestos de aril o heteroaril amida
CY1109498T1 (el) 18-μεθυλο-19-νορ-17-πρεγν-4-ενο-21,17-καρβολακτονες καθως και φαρμακευτικα σκευασματα που τις περιεχουν
ATE538124T1 (de) Imidazokondensierte tricyclische verbindungen auf thiazoloä4,5-büpyridin-basis und pharmazeutische zusammensetzungen damit
MXPA05010824A (es) Compuestos biciclicos como antagonistas del receptor nr2b.
CY1111980T1 (el) Παραγωγα του αμιδιου τα οποια φερουν ενα υποκαταστατο του κυκλοπροπυλαμινοκαρβονυλιου και χρησιμευουν ως αναστολεις κυτταροκινης
CR10974A (es) Inhibidores de carboxipeptidasa b plasmatica (divisional)
UY27685A1 (es) Indolil-urea derivados de tienopiridinas útiles como agentes antiangiogénicos, y procedimientos para su uso
ATE233754T1 (de) Diphenyl-piperidin derivate
UY28377A1 (es) Agentes terapeuticos
ATE57919T1 (de) Triazinderivate, verfahren zur herstellung der derivate und die derivate als wirksamen bestandteil enthaltende herbizide.
DE60201259D1 (de) Chemische verbindungen
BR0311491A (pt) Composto, composição farmacêutica, uso de um composto, e, método terapêutico para tratar câncer em um mamìfero

Legal Events

Date Code Title Description
FB Suspension of granting procedure